(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Trial ID or NCT#

NCT04996875

Status

recruiting iconRECRUITING

Purpose

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

Official Title

A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

Justin Abuel
650-723-1367

SEND MESSAGE

View on ClinicalTrials.gov